Fagron N.V. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
342,711.00
447,056.00
427,560.00
421,839.00
436,934.00
471,679
Cost of Goods Sold (COGS) incl. D&A
277,662.00
354,331.00
354,076.00
352,897.00
363,791.00
392,207
Gross Income
65,049.00
92,725.00
73,484.00
68,942.00
73,143.00
79,472
EBIT
-
90,983.00
-
69,322.00
71,955.00
71,755
Unusual Expense
1,285.00
399.00
47,572.00
52,380.00
713.00
131
Non Operating Income/Expense
4,249.00
2,514.00
4,536.00
2,690.00
2,191.00
1,338
Interest Expense
14,189.00
23,977.00
44,049.00
37,709.00
21,336.00
16,094
Pretax Income
48,821.00
69,852.00
16,108.00
6,364.00
55,965.00
54,835
Income Tax
6,997.00
26,662.00
8,840.00
11,748.00
8,918.00
11,553
Consolidated Net Income
41,824.00
43,190.00
24,948.00
18,112.00
47,047.00
43,282
Net Income
41,752.00
43,260.00
25,264.00
18,517.00
46,658.00
42,863
Net Income After Extraordinaries
115,606.00
70,293.00
151,800.00
16,472.00
46,658.00
43,240
Net Income Available to Common
32,102.00
43,694.00
202,328.00
20,562.00
46,658.00
42,486
EPS (Basic)
0.98
0.49
5.26
0.38
0.65
0.59
Basic Shares Outstanding
32,979.10
33,099.60
33,686.10
53,957.00
71,740.00
71,740
EPS (Diluted)
0.96
0.48
5.98
0.38
0.65
0.59
Diluted Shares Outstanding
33,502.10
33,486.00
33,816.30
53,957.00
71,877.00
71,969
EBITDA
73,923.00
107,326.00
84,216.00
87,501.00
87,046.00
87,992
Other Operating Expense
113.00
1,742.00
2,366.00
380.00
1,188.00
3,238
Non-Operating Interest Income
1,038.00
731.00
1,147.00
11,713.00
2,442.00
643
Minority Interest Expense
72.00
70.00
316.00
405.00
389.00
419

About Fagron

View Profile
Address
Venecoweg 20A
Nazareth VL 9810
Belgium
Employees -
Website http://www.fagron.com
Updated 07/08/2019
Fagron NV engages in the provision of development, marketing, and distribution of healthcare products and services. It operates through the following segments: Fagron Specialty Pharma Services (FSPS); Fagron Trademarks (FTM); Fagron Essentials (FE); and HL Technology. The FSPS segment refers to all personalized medication that is prepared in sterile and non-sterile compounding facilities in Europe, the United States, Colombia and South Africa.